The common shares of Spackman Equities Group trades on the TSX Venture Exchange under the symbol SQG. Visit www.spackmanequities.com for further information.

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

Test The FDA has expanded the approval for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to include patients with HR+, HER2-ultralow metastatic breast cancer who may benefit from ...

If breast cancer is diagnosed at an early stage, it has a higher chance of being cured. Therefore, it is important that you get tests done at regular intervals as it can help in early diagnosis of ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast cancer who may be candidates for antibody-drug ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo and Roche.